BKM120
Metastatic or Locally Advanced Solid Tumors
Novartis PharmaceuticalsSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Metastatic or Locally Advanced Solid Tumors cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
TRASTUZUMAB Novartis Pharmaceuticals | Phase 1 | CC |
y101d Wuhan YZY Biopharma Co., Ltd. | Phase 1 | CC |
DACTOLISIB Novartis Pharmaceuticals | Phase 1 | CC |
Sorafenib Hospices Civils de Lyon | Phase 1 | CC |
Everolimus Hospices Civils de Lyon | Phase 1 | CC |
Same molecule, other indications
BKM120 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →